Since 1964 — when John Bergan, M.D., completed the first successful kidney transplant at what is now Northwestern Memorial Hospital — more than 7,000 of the surgeries have taken place at Northwestern Medicine.
Today, John Friedewald, M.D., his study team, and Northwestern’s Clinical Research Unit (CRU) are collaborating to investigate new ways to make even more patients eligible for kidney transplants.
“Our clinical trial is investigating a novel drug compound designed to deplete plasma cells in order to reduce levels of anti-HLA antibodies in patients awaiting a kidney transplant,” says Friedewald, professor of Medicine in the Division of Nephrology and Hypertension, and of Surgery in the Division of Organ Transplantation…
Read the full article here.
